This new CPB states that romosozumab-aqqg (Evenity) subcutaneous injection is considered medically necessary for the treatment of osteoporosis or for osteopenia with a high pre-treatment FRAX fracture probability in postmenopausal members at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or members who have failed or are intolerant to other available osteoporosis therapy.